Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Alexion Announces the Appointment of John T. Mollen to Its Board of Directors

Business Wire April 17, 2014

Researchers to Present New Data on Asfotase Alfa in Infants and Juveniles with Hypophosphatasia at the Joint Meeting of the Pediatric Academic Societies and the Asian Society for Pediatric Research

Business Wire April 11, 2014

Alexion Pharmaceuticals to Report First Quarter 2014 Results on Thursday, April 24, 2014

Business Wire April 10, 2014

Alexion Revises Upward 2014 Financial Guidance for Revenues and non-GAAP EPS

Business Wire March 10, 2014

Collaborations, Conferences, and Recognitions - Analyst Notes on Illumina, Alexion, Medtronic, Sirona, and NPS Pharmaceuticals

PR Newswire March 5, 2014

Alexion to Present at the Barclays Global Healthcare Conference

Business Wire March 5, 2014

Alexion Joins Patient Organizations Worldwide in Recognizing Rare Disease Day 2014

Business Wire February 28, 2014

Alexion to Present at the Cowen and Company 34th Annual Health Care Conference

Business Wire February 25, 2014

European Commission Grants Orphan Drug Designation to Soliris® (Eculizumab) for Prevention of Delayed Graft Function (DGF) after Solid Organ Transplantation

Business Wire February 24, 2014

Alexion Reports Fourth Quarter and Full Year 2013 Results and Provides Financial Guidance for 2014

Business Wire January 30, 2014

FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients

Business Wire January 21, 2014

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2013 Results on Thursday, January 30, 2014

Business Wire January 16, 2014

Alexion Pharmaceuticals and Moderna Therapeutics Announce Exclusive Strategic Agreement to Develop Messenger RNA Therapeutics(TM) for Rare Diseases

Business Wire January 13, 2014

Alexion to Present at the JP Morgan 32nd Annual Healthcare Conference

Business Wire January 8, 2014

Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris® (eculizumab) Concentrated Solution for Intravenous Infusion

Business Wire December 13, 2013

New Data Presented at ASH Annual Meeting Enhance Understanding of PNH and aHUS to Provide Optimal Care for Patients with These Life-threatening Disorders

Business Wire December 8, 2013

Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)

Canada NewsWire November 9, 2013

Soliris® (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome (aHUS)

Business Wire November 9, 2013

Researchers to Present Clinical Trial Data With Soliris® (eculizumab) Treatment in Both Approved Indications - PNH and aHUS - at ASH Annual Meeting

Business Wire November 7, 2013

Alexion to Present at Credit Suisse 2013 Healthcare Conference

Business Wire November 7, 2013